Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Tumor Ablation Market Worth $462.0 Million by 2019

    According to a new market research report "Tumor Ablation Market by Procedure Volume, Technology (RF, Microwave, Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver Cancer, Lung Cancer, Kidney Cancer, Bone Metastasis) - Global Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation Market is expected to reach around $462.0 Million growing at a CAGR of 11.50% by 2019.

  • Dr. Reddy’s starts new Center of Excellence for Fully Integrated Formulation Development Services

    Dr. Reddy’s Custom Pharmaceutical Services (CPS) division has expanded its existing custom service facilities with a new formulation development laboratory in Miyapur, Hyderabad, India. Bringing together the existing API development team and the formulation teams at one location will accelerate project timelines, reduce costs and simplify licensing processes for CPS’ pharma customers.

  • First WHO Collaborating Centre in South East Asia Region at India

    World Health Organization (WHO) Country office for India in collaboration with the Ministry of Health and Family Welfare, Government of India and National Health Systems Resource Centre (NHSRC), formally announced the commencement of National Health Systems Resource Centre (NHSRC), as the WHO Collaborating Centre for Priority Medical Devices and Health Technology Policy.

  • Novartis presents Cosentyx™ two-year efficacy and safety data showing sustainable effect in psoriasis patients

    Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx™ (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. Results were presented for the first time in a late-breaking session at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) in San Francisco. Cosentyx is the first and only interleukin-17A (IL-17A) antagonist approved to treat adult moderate-to-severe plaque psoriasis patients.

  • 'Hiding Place' of HIV in Cells Discovered

    Scientists have discovered the hiding place of HIV in cells, an advance that may lead to new therapies to combat the deadly virus. Researchers at the International Center for Genetic Engineering and Biotechnology (ICGEB) in Italy have photographed the structure of nucleic lymphocytes with a high-resolution microscopy technique to discover the "hiding place" of HIV.

  • First-ever human population adaptation to arsenic identified

    Scientists have identified the first-ever evidence of a human population uniquely adapted to tolerate the toxic chemical arsenic in the Andes Mountains of Argentina. A Swedish research team led by Karolinska Institutet and Uppsala University professor Karin Broberg, performed a genome wide survey from a group of 124 Andean women screened for the ability to metabolise arsenic (measured by levels in the urine).

  • Alzheimer's Amyloid Clumps found in Young Adult Brains

    Scientists have for the first time found that an abnormal protein whose accumulation in the brain is a hallmark of Alzheimer's disease starts building up inside neurons of people as young as 20. It has long been known that amyloid accumulates and forms clumps of plaque outside neurons in ageing adults and in Alzheimer's but this is the first time amyloid accumulation has been shown in such young human brains, researchers said.

  • Gorilla Origins of Two Human Aids Virus Lineages Confirmed

    Two of the four known groups of human AIDS viruses originated in western lowland gorillas in Cameroon, according to a new study. An international team of scientists from the Perelman School of Medicine at the University of Pennsylvania, the University of Montpellier, the University of Edinburgh, and colleagues conducted a comprehensive survey of simian immunodeficiency virus (SIV) infection in African gorillas.

  • Emergent joins with GSK & NIAID for the production of Ebola Vaccine

    Emergent BioSolutions under several agreements signed with the Oxford university, GSK and the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) respectively, it has manufactured a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) anticipated for use in a Phase 1 clinical study to be conducted by Professor Adrian Hill of the Jenner Institute.

Subscribe to Pharma News

Search this website